Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Full description

Bibliographic Details
Main Authors: Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Vito Longo, Angela Calabrese, Antonella Argentiero, Sabina Delcuratolo, Antonio Giovanni Solimando, Andrea Casadei-Gardini, Nicola Silvestris
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Medicina
Subjects:
sorafenib
hepatocellular carcinoma
prognostic factors
predictive factors
Online Access:https://www.mdpi.com/1010-660X/55/10/707

Internet

https://www.mdpi.com/1010-660X/55/10/707

Similar Items